Index 45. Jahrgang, 2006 Inhalte Keywords

Transkript

Herausgeber:
Deutsche Gesellschaft für Nuklearmedizin
(DGN)
Österreichische Gesellschaft für
Nuklearmedizin (ÖGN)
Schweizerische Gesellschaft für
Nuklearmedizin (SGNM/SSNM)
Schattauer GmbH
Schriftleiter:
O. Schober (verantwortlich)
Index 45. Jahrgang, 2006
Inhalte
Keywords
Sektionseditoren:
P. Bartenstein (Kasuistik, Leserbriefe)
F. Bengel (Kardiologie, Pulmologie)
H. A. Bockisch (Onkologie,
Systemerkrankungen)
T. Kuwert (Neuromedizin, Nephrologie,
Gastroenterologie)
A. A. Lammertsma (Medizin. Physik,
Strahlenschutz)
Chr. Eilles (Endokrinologie,
Gesundheitsökonomie)
P. A. Schubiger (Radiochemie,
Radiopharmazie)
I. Virgolini (Molecular Therapy)
I. Carrio (EJNM/EANM)
H. Schelbert (SNM/JNM)
E. Fleck (Kardiologie)
G. Gademann (Radioonkologie)
H.-J. Heinze (Neurologie)
H. Jürgens (Onkologie)
E. Rummeny (Radiologie)
Schlüsselworte
Autoren
Honorar-Editoren:
U. Büll
H. Schicha
http://www.nuklearmedizin-online.de
Inhalt – Nuklearmedizin 2006; 45 (1-6)
Abstracts
44. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin .......................2: A4–A126
7th Annual Congress Swiss Society of Nuclear Medicine...................................3: A134–A146
6. Nationales Symposium der Österreichischen Gesellschaft für
Nuklearmedizin ...................................................................................................6: A148–A161
Editorial
Chr. Reiners
Iodblockade der Schilddrüse bei kerntechnischen Unfällen .................................................97
Originalarbeiten – Original Articles
A. Stamm-Meyer, D. Noßke, P. Schnell-Inderst, M. Hacker, K. Hahn and G. Brix
Diagnostic nuclear medicine procedures in Germany between 1996 and 2002
Nuklearmedizinische Untersuchungen in Deutschland zwischen 1996 und 2002 .................1
O. Lindner, J. Vogt, A. Kammeier, E. Fricke, J. Holzinger, B. Lamp, D. Baller, D.
Horstkotte, W. Burchert
Cardiac resynchronisation therapy
Kardiale Resynchronisationstherapie ....................................................................................10
S. Höpfner, C. Krolak, S. Kessler, R. Tiling
Preoperative imaging of Charcot neuro-arthropathy
Präoperative Bildgebung bei diabetisch-neuropathischer Osteoarthropathie.......................15
M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha
Therapy for non-toxic multinodular goiter
Therapiekonzepte der euthyreoten Struma nodosa..............................................................21
M. Schünemann, G. Heidrich, C.O. Sahlmann, U. Siefker, H. Luig, C. Werner, E.
Brunner, J. Meller
Improvement of tomographic reconstruction in bone SPECT
Optimierung der tomographischen Rekonstruktion in der Skelett-SPECT ...........................35
O. Prante, C. Hocke, S. Löber, H. Hübner, P. Gmeiner, T. Kuwert
Tissue distribution of radioiodinated FAUC 113
Bioverteilung von Radioiod-markiertem FAUC 113...............................................................41
M. Henze, N. Özdemir-Sahin, P. Hipp, W. Mier, M. Eisenhut, J. Debus, U.
Haberkorn
Comparison of diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT
Vergleich der diagnostischen Genauigkeit von 18F-FDG-PET, 123I-IMT- und 99mTc-MIBISPECT ...................................................................................................................................49
R. Klett, M. Puille, D. Steiner, R. Bauer
Radiation synovectomy of the knee joint
Radiosynoviorthese des Kniegelenkes..................................................................................57
M. Gutberlet, S. Mehl, M. Fröhlich, H. Hausmann, M. Plotkin, J. Ruf, T. Denecke,
B. Spors, M. Grothoff, R. Hetzer, R. Felix, H. Amthauer
Determination of ventricular volumes in coronary artery disease: Comparison of two
gated SPECT analysis tools with MRI
Bestimmung ventrikulärer Volumina bei koronarer Herzerkrankung: Vergleich zweier
Gated-SPECT-Analyseverfahren mit MRT............................................................................63
II
M. Koehli, D. Monbaron, J. O. Prior, M. L. Calcagni, M. Fivaz-Arbane, J. C.
Stauffer, R. C. Gaillard, A. Bischof Delaloye, J. Ruiz
SPECT myocardial perfusion imaging: Long-term prognostic value in diabetic patients
with and without coronary artery disease
Myokardperfusion SPECT: Stellenwert in der Langzeit-Prognose diabetischer
Patienten mit und ohne koronarer Herzkrankheit..................................................................74
L. Geworski, K. Zöphel, A. Rimpler, I. Barth, M. Lassmann, D. Sandrock, A.
Zander, T. Halm, H. Hänscheid, M. Hofmann, Chr. Reiners, D. L. Munz
Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial
Strahlenexposition bei der 90Y-Zevalin-Therapie: Ergebnisse einer prospektiven
multizentrischen Studie..........................................................................................................82
W. Römer, A. Nömayr, H. Greess, E. Fiedler, G. Platsch, B. Schuler-Thurner, A.
Pfahlberg, T. Hothorn, G. Schuler, J. Hornegger, W. Bautz, T. Kuwert
Retrospective interactive rigid fusion of 18F-FDG-PET and CT: Additional diagnostic
information in melanoma patients
Retrospektive interaktive starre Fusion von 18F-FDG-PET und CT: zusätzliche
diagnostische Information bei Patienten mit malignem Melanom.........................................88
H. Vogt, H. Wengenmair, J. Kopp, R. Dorn, I. Otto, J. Sciuk
Radioiodine therapy for combined disseminated and nodular thyroid autonomy
Radioiodtherapie bei kombinierter Schilddrüsenautonomie................................................101
J. Bucerius, C. Herkel, A. Y. Joe, C. Altehoefer, J. Finke, E. Moser, M. J. Reinhardt
F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non
Hodgkin's lymphoma
18
F-FDG-PET und konventionelle Bildgebung zur Diagnostik von Morbus Hodgkin und
Non-Hodgkin-Lymphomen...................................................................................................105
18
R. Czepczyński, I. Smolarek, D. Rogacka, M. Kaźmierczak, H. Wysocki, J.
Sowiński
Myocardial perfusion SPECT with dipyridamole stress test in cardiac syndrome X
Myokardperfusionsszintigraphie mit dem Dipyridamol-Belastungstest im kardialen
Syndrom X ...........................................................................................................................111
B. Schommartz, K. Cupisti, C. Antke, D. Schmidt, W.-T. Knoefel, H.-W. Müller
Localisation of parathyroid glands using planar 99mTc-sestamibi scintigraphy
Lokalisation von Nebenschilddrüsenadenomen mit planarer 99mTc-SestamibiSzintigraphie ........................................................................................................................115
M. Gotthardt, M. Stübinger, J. Pansegrau, B. Buchwald, J. Goecke, A. Pfestroff, F.
H. M. Corstens, T. M. Behr
Decrease of 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s
Abfall des 99mTc-Uptakes in autonomem Schilddrüsengewebe in Deutschland seit den
1970er Jahren......................................................................................................................122
M.-J. Martínez, Y. Bercier, M. Schwaiger, S. I. Ziegler
PET/CT BiographTM Sensation 16
PET/CT BiographTM Sensation 16 .....................................................................................126
G. Glatting, T. Kull, N. M. Blumstein, D. Bunjes, B. Neumaier, A. K. Buck, S. N.
Reske
Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies
Dosimetrie mit 188Re-markierten monoklonalen anti-CD66 Antikörpern .............................134
III
P. Männer, B. Tege, E. Fuchs, H. G. Reicherzer, M. Kurz, J. Marienhagen, J.
Schönberger, W. Börner, Chr. Eilles
Integration of PACS and HIS into the workflow of a nuclear medicine department
Integration von PACS und KIS in den Workflow einer nuklearmedizinischen Abteilung....139
M. Schmidt, T. Simon, B. Hero, W. Eschner, M. Dietlein, F. Sudbrock, R. Bongartz,
F. Berthold, H. Schicha
Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4
neuroblastoma?
Gibt es einen Nutzen durch die 131I-MIBG-Therapie bei der Behandlung von Kindern
mit Neuroblastom Stadium 4? .............................................................................................145
B. Meller, K. Sommer, J. Gerl, K. von Hof, A. Surowiec, E. Richter, B. Wollenberg,
M. Baehre
High energy probe for detecting lymph node metastases with 18F-FDG in patients with
head and neck cancer
Hochenergie-Sonde zur Detektion von Lymphknotenmetastasen mit 18F-FDG bei
Patienten mit Kopf-Hals-Tumoren .......................................................................................153
R. Krause, C. Piswanger-Soelkner, R. W. Lipp, F. Daxböck, W. J. Schnedl, S.
Hoier, E. C. Reisinger
Somatostatin receptor scintigraphy in patients with cat-scratch disease
Somatostatinrezeptor-Szintigraphie bei Patienten mit Katzenkratzkrankheit .....................160
M. Beheshti, A. Khorsand, S. Graf, G. Dobrozemsky, S. Oezer, K. Kletter, R.
Dudczak, C. Pirich
FDG gamma camera PET equipped with one inch crystal and XCT
Mit Ein-Zoll-Kristallen ausgerüstete Gammakamera-PET und -XCT..................................163
S. Graf, A. Khorsand, G. Stix, S. Nekolla, A. Becherer, K. Kletter, R. Dudczak, H.
Sochor, G. Maurer, G. Porenta
Attenuation correction for myocardial perfusion imaging
Myokardperfusionsszintigraphie mit Schwächungskorrektur ..............................................171
H. Amthauer, T. Denecke, B. Hildebrandt, R. Rühl, A. Miersch, A. Nicolaou, J. Ruf,
M. Plotkin, E. L. Hänninen, C. Stroszczynski, M. Gutberlet, J. Langrehr, H. Riess,
J. Ricke
Evaluation of patients with liver metastases from colorectal cancer for locally
ablativetreatment with laser induced thermotherapy
Evaluation von Patienten mit Lebermetastasen kolorektaler Karzinome vor
lokalablativer Therapie mittels Laser-induzierter Thermotherapie ......................................177
J. H. Risse, C. Rabe, D. Pauleit, K. Reichmann, C. Menzel, F. Grünwald, H. Strunk,
H.-J. Biersack, H. Palmedo
Therapy of hepatocellular carcinoma with iodine-131-lipiodol
Therapie des hepatozellulären Karzinoms mit Iod-131-Lipiodol .........................................185
A. Lange-Nolde, T. Zajic, M. Slawik, I. Brink, M. Reincke, E. Moser, S. Hoegerle
PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary
hyperparathyroidism
PET mit 18F-DOPA zur Darstellung von Nebenschilddrüsenadenomen bei primären
Hyperparathyreoidismus......................................................................................................193
G. Henriksen, M. E. Spilker, T. Sprenger, A. I. Hauser, S. Platzer, H. Boecker, T. R.
Toelle, M. Schwaiger, H.-J. Wester
Gender dependent rate of metabolism of the opioid receptor-PET ligand
[18F]fluoroethyl-diprenorphine
Geschlechtsspezifische Unterschiede im Metabolismus des opioidergen PET-Liganden
[18F]Fluorethyl-diprenorphin .................................................................................................197
IV
J. K. Lee, R. S. Liu, S. Y. Wu, W. S. Huang, M. C. Chou
Thallium-201 scan in evaluating thyroid nodules following equivocal fine-needle
aspiration cytology
Thallium-201-Szintigraphie zur Beurteilung von Schilddrüsenknoten bei unklarer
Feinnadelaspirationszytologie .............................................................................................201
M. Gotthardt, C. Rubner, A. Bauhofer, F. Berce, W. J. G. Oyen, J. Goecke, A.
Pfestroff, A. Schlieck, F. H. Corstens, M. Béhé, T. M. Behr
What is the best pre-therapeutic dosimetry for successful radioiodine therapy of
multifocal autonomy?
Was ist die beste prätherapeutische Dosimetrie für eine erfolgreiche Radioiodtherapie
multifokaler Autonomien? ....................................................................................................206
S. Dunkelmann, H. Künstner, E. Nabavi, U. Eberlein, P. Groth, C. Schümichen
Lithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the
intrathyroidal effective half-life of radioiodine
Lithium als Zusatz zur Radioiodtherapie bei Morbus Basedow zur Verlängerung der
intrathyroidalen effektiven Halbwertszeit von Radioiod.......................................................213
K. P. Schäfers, R. Raupach, T. Beyer
Combined 18F-FDG-PET/CT imaging of the head and neck
Kombinierte 18F-FDG-PET/CT-Bildgebung im HNO-Bereich..............................................219
M. Voth, R. Klett, P. Lengsfeld, G. Stephan, E. Schmid
Biological dosimetry after yttrium-90 citrate colloid radiosynoviorthesis
Biologische Dosimetrie nach Radiosynoviorthese mit einem Yttrium-90-Zitratkolloid........223
L. S. Freudenberg, T. Beyer, S. P. Müller, R. Görges, A. Hopfenbach, A. Bockisch
Evil radioactivity
Radioaktivität ist böse..........................................................................................................229
I. Buchmann, T. Hansen, C. Brochhausen, W. Kneist, K. Oberholzer, T.
Junginger, M. Schreckenberger, P. Bartenstein
FDG-PET in the initial staging of squamous cell oesophageal carcinoma
FDG-PET zum initialen Staging bei Plattenepithelkarzinom des Ösophagus ....................235
N. Döbert, A. F. Kovács, C. Menzel, K. Engels, W. T. Kranert, F. Grünwald
FDG uptake after intraarterial chemotherapy in head and neck cancer
FDG-Aufnahme nach intraarterieller Chemotherapie bei Kopf-Hals-Tumoren ...................243
S. Graf, M. Nikfardjam, A. Khorsand, S. Ofluoglu, S. Nekolla, R. Dudczak, G.
Maurer, K. Kletter, K. Huber, C. Pirich
13
N-ammonia rest/stress PET
13
N-Ammoniak-PET .............................................................................................................248
F. Sudbrock, W. Eschner, M. Schmidt, T. Simon, B. Hero, H. Schicha
Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG
Dosimetrie bei der Therapie von Neuroblastomen mit 131I-mIBG .......................................254
W. U. Kampen, E. Matis, N. Czech, Z. Soti, S. Gratz, E. Henze
Serious complications after radiosynoviorthesis
Gravierende Komplikationen nach Radiosynoviorthese .....................................................262
G. Glatting, M. Landmann, A. Wunderlich, T. Kull, F. M. Mottaghy, S. N. Reske
Internal radionuclide therapy
Therapie mit offenen Radionukliden....................................................................................269
H. Lerch, A. Jigalin
Molecular imaging and molecular guided therapy
Molekulare Bildgebung und molekular geführte Therapie...................................................273
V
CME-Fortbildung – Education
M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha
Therapy for non-toxic multinodular goiter
Therapiekonzepte der euthyreoten Struma nodosa..............................................................21
L. Geworski, K. Zöphel, A. Rimpler, I. Barth, M. Lassmann, D. Sandrock, A.
Zander, T. Halm, H. Hänscheid, M. Hofmann, Chr. Reiners, D. L. Munz
Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial
Strahlenexposition bei der 90Y-Zevalin-Therapie: Ergebnisse einer prospektiven
multizentrischen Studie..........................................................................................................82
J. Bucerius, C. Herkel, A. Y. Joe, C. Altehoefer, J. Finke, E. Moser, M. J. Reinhardt
F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non
Hodgkin's lymphoma
18
F-FDG-PET und konventionelle Bildgebung zur Diagnostik von Morbus Hodgkin und
Non-Hodgkin-Lymphomen...................................................................................................105
18
M. Schmidt, T. Simon, B. Hero, W. Eschner, M. Dietlein, F. Sudbrock, R. Bongartz,
F. Berthold, H. Schicha
Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4
neuroblastoma?
Gibt es einen Nutzen durch die 131I-MIBG-Therapie bei der Behandlung von Kindern
mit Neuroblastom Stadium 4? .............................................................................................145
S. Dunkelmann, H. Künstner, E. Nabavi, U. Eberlein, P. Groth, C. Schümichen
Lithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the
intrathyroidal effective half-life of radioiodine
Lithium als Zusatz zur Radioiodtherapie bei Morbus Basedow zur Verlängerung der
intrathyroidalen effektiven Halbwertszeit von Radioiod.......................................................213
I. Buchmann, T. Hansen, C. Brochhausen, W. Kneist, K. Oberholzer, T.
Junginger, M. Schreckenberger, P. Bartenstein
FDG-PET in the initial staging of squamous cell oesophageal carcinoma
FDG-PET zum initialen Staging bei Plattenepithelkarzinom des Ösophagus ....................235
Der besondere Fall – Special Case Report
T. Athanasoulis, J. Koutsikos, K. Korovesis, J. Bokos, C. Zerva
Supernumerary parathyroid glands with an unusual ectopic location in recurrent
secondary hyperparathyroidism ........................................................................................... N4
A. Hofmann, P. John, M. P. Schaffarich, H. Sinzinger, A. Staudenherz
Statins as a new therapeutic approach in dedifferentiated thyroid cancer? ...................... N28
R. Hodek-Wuerz, M. A. Walter, J. Mueller-Brand
Puzzling intestinal uptake in 99mTc-DPD bone scintigraphy ............................................... N41
F. G. Fuechsel, S. Weidner, T. Krause
Focal pelvic uptake in 18F-FDG PET due to a contraceptive device.................................. N42
F. Büther, K. P. Schäfers, L. Stegger, F. Range, R. Fischbach, T. Wichter, M.
Schäfers, O. Schober
Artifacts caused by contrast agents and patient movement in cardiac PET-CT................ N53
G. Zettinig, F. Wrba, F. Trautinger, P. Peloschek, A. Luger
Necrobiotic panniculitis due to repeated insulin injection................................................... N64
VI
Keywords – Nuklearmedizin 2006; 45 (1-6)
Activity leakage ..................... 57
Anti-CD66............................ 134
Attenuation correction . 163, 171
Autonomy ............................ 122
Autoradiography .................... 41
Benign thyroid disorder ....... 122
Biological dosimetry ............ 223
Bone detritus ......................... 15
Bone scintigraphy.................. 35
β-rays .................................... 82
Bremsstrahlung ............... 57, 82
Cancer therapy.................... 185
Cardiac MRI .......................... 63
Cardiac syndrome X............ 111
Cardiac volumetry ................. 63
Cat-scratch disease............. 160
Cervical lymph nodes .......... 243
Chromosome aberration...... 223
Cold thyroid nodule ............. 201
Collective effective dose.......... 1
Colorectal cancer ................ 177
Computed tomography........ 105
Coronary angiography......... 111
Coronary artery disease
............................. 63, 74, 248
Coronary flow reserve ......... 248
Cultural anthropology .......... 229
D4 receptor............................ 41
Dedicated PET .................... 163
Diabetes mellitus ................... 74
Diabetic neuropathic
osteoarthropathy................ 15
Diagnostic nuclear medicine.... 1
Diprenorphine...................... 197
Dipyridamole ....................... 111
Dosimetrie .. 101, 134, 206, 213,
254, 269
Dual-phase technique ......... 115
Endocrinology...................... 206
18
F-DOPA ............................ 193
F-FDG............................... 153
FDG-PET............... 88, 235, 243
Filtered backprojection .......... 35
Fine-needle aspiration cytology
......................................... 201
Fluorine-18 .......................... 197
Frequency of procedures ........ 1
18
Gamma camera PET........... 163
Gated SPECT........................ 63
Gender differences.............. 197
Graves' disease................... 213
Head and neck ............ 153, 219
Heart failure..................... 10, 63
Hepatocellular carcinoma.... 185
High energy gamma
probe ............................... 153
High risk neuroblastoma...... 145
HIS ...................................... 139
Hodgkin's disease ............... 105
Homocysteine ......................248
123
I-IMT SPECT .....................49
I................................145, 206
Ibritumomab tiuxetan .............82
Image fusion ..........................88
Infection ...............................262
Intraarterial
chemotherapy ..................243
Iodine-131-lipiodol ...............185
Iterative reconstruction ..........35
131
Laser induced
thermotherapy ..................177
Left bundle branch block........10
Levothyroxine ........................21
Lithium .................................213
Liver metastases..................177
Long term analysis...............185
Low grade astrocytoma .........49
Magnetic resonance
imaging ......................15, 105
Malignancy...........................201
Medical anthropology...........229
Melanoma..............................88
Metabolism ..........................197
Metal artifacts ......................219
Metastases ..................235, 243
MIBG-Therapie ....................254
MIBI scintigraphy .................193
Modeling ..............................197
Molecular guided
therapy .............................273
Molecular imaging................273
Myocardial ischemia ..............74
Myocardial perfusion
imaging ............................171
Myocardial scar......................63
Myocardial viability...............163
Necrosis...............................262
NEMA NU 2-2001 ................126
Neuroblastom ......................254
Noise-equivalent
count-rate.........................126
Non-Hodgkin's lymphoma....105
Non-toxic multinodular
goiter ..................................21
Nuclear medicine workflow ..139
Oesophageal cancer............235
Oxygen consumption .............10
Primary hyper-parathyreoidism
................................ 115, 193
Prognostic value.................... 74
Radiation............... 82, 223, 229
Radiation synovectomy ......... 57
Radioimmunotherapy .... 82, 134
Radioiodine therapy
..21, 101, 122, 206, 213, 229,
Radioligand ........................... 41
Radionuclide therapy .......... 269
Radiosynoviorthesis .... 223, 262
Radiotherapy......................... 49
Recombinant human TSH..... 21
Reconstruction algorithms..... 35
Residence time ........... 134, 269
RIS ...................................... 139
ROC analysis ........................ 49
SAP R/3 .............................. 139
Sestamibi-scintigraphy ........ 115
Skin dose .............................. 82
Somatostatin receptor
scintigraphy ..................... 160
Single-photon emission
computed tomography, SPECT
............ 35, 74, 111, 171, 254
Spiral computed
tomography........................ 88
Squamous cell
carcinoma................ 235, 243
Stage 4 neuroblastoma ....... 145
Standardized uptake
value................................ 243
Subtraction technique ......... 115
Synovitis.............................. 262
99m
Tc-MIBI SPECT ................ 49
Tc-Sestamibi .................. 111
TcTUs ................................. 122
Thallium-201 scan............... 201
Thrombosis ......................... 262
Thyroid ........................ 101, 106
Tomographic data ............... 269
Treatment planning ..... 134, 269
Tumour staging ................... 235
99m
Ultrasonography.................. 193
Yttrium-90 ............... 57, 82, 223
Zevalin .................................. 82
PACS...................................139
Patient exposure......................1
Perception ...........................229
Perfusion ...............................10
Phantom study.......................57
Pico-3D electronics..............126
Plummers´ disease ..............122
Polar map analysis ..............171
Portal vein thrombosis .........185
Positron emission tomography,
PET10, 15, 88, 105, 126, 153,
171, 177, 193, 197, 219, 248
VII
Schlüsselworte – Nuklearmedizin 2006; 45 (1-6)
Abschwächungskorrektur.... 163
Aktivitäsabtransport............... 57
Anti-CD66............................ 134
Autonomie ........................... 122
Autoradiographie ................... 41
Benigne
Schilddrüsenerkrankung .. 122
Bildfusion............................... 88
Biologische Dosimetrie........ 223
Bremsstrahlung ............... 57, 82
β-Strahlung............................ 82
Chromosomenaberration..... 223
Computertomographie......... 105
D4-Rezeptor .......................... 41
Diabetes mellitus ................... 74
Diabetisch-neuropatische
Osteoarthropathie .............. 15
Diprenorphin........................ 197
Dipyridamol ......................... 111
Dosimetrie .. 101, 134, 206, 213,
254, 269
Endokrinologie..................... 206
Energiedosis........................ 254
Euthyreose ............................ 21
18
F-DOPA ............................ 193
F-FDG....................... 153, 163
18
F-FDG PET......................... 49
FDG-PET....... 88, 177, 235, 243
Feinnadelaspirationszytologie .......................... 201
Fluor-18............................... 197
18
Gammakamera-PET ........... 163
Ganzkörperszintigraphie ..... 254
GatedSPECT......................... 63
Gefilterte Rückprojektion ....... 35
Geschlechtsspezifische
Unterschiede.................... 197
Hautdosis .............................. 82
Hepatozelluläres Karzinom.. 185
Herzinsuffizienz ............... 10, 63
HNO .................................... 219
Hochenergiesonde .............. 153
Hochrisiko-Neuroblastom .... 145
Homocystein........................ 248
123
I-IMT SPECT ..................... 49
I ....................................... 206
131
I-MIBG-Therapie.............. 145
Ibritumomab Tiuxetan............ 82
Infektion............................... 262
Intraarterielle
Chemotherapie ................ 243
Iod-131-Lipiodol................... 185
Iterative Rekonstruktion......... 35
131
Kalter
Schilddrüsenknoten..........201
Kardiale MRT.........................63
Kardiale Volumetrie ...............63
Kardiales Syndrom X ...........111
Katzenkratzkrankheit ...........160
KIS.......................................139
Knochendetritus.....................15
Kollektive effektive Dosis .........1
Kolorektales Karzinom.........177
Kombinierte
Schilddrüsenautonomie....101
Kopf-Hals-Tumore ...............153
Koronarangiographie ...........111
Koronare Flussreseve..........248
Koronare
Herzerkrankung....63, 74, 248
Kulturanthropologie..............229
Langzeitanalyse...................185
Laser-induzierte
Thermotherapie................177
Lebermetastasen .................177
Levothyroxin ..........................21
Linksschenkelblock................10
Lithium .................................213
Magnetresonanztomographie ...............15, 105
Malignität .............................201
Medizinethnologie................229
Melanom ................................88
Metabolismus.......................197
Metallartefakte .....................219
Metastasierung ....................235
MIBG-Therapie ....................254
MIBI-Szintigraphie ...............193
Modeling ..............................197
Molekular geführte
Therapie...........................273
Molekulare Bildgebung ........273
Morbus Basedow .................213
Morbus Hodgkin...................105
Myokardiale Vitalität.............163
Myokardischämie...................74
Myokardnarbe........................63
Myokardperfusion ..........74, 171
Nekrose ...............................262
NEMA NU 2-2001 ................126
Neuroblastom ......................254
Neuroblastom Stadium 4 .....145
Niedriggradiges Astrozytom...49
Non-Hodgkin-Lymphom.......105
Phantommessung ................. 57
Pico-3D-Elektronik .............. 126
Plattenepithel
karzinom .................. 235, 243
Polar-Map-Analyse.............. 171
Primärer Hyperparathyreoidismus .......... 115, 193
Radioimmuntherapie ..... 82, 134
Radioiodtherapie .. 21, 101, 122,
206, 213, 229
Radioligand ........................... 41
Radionuklidtherapie ............ 269
Radiosynoviorthese
.......................... 57, 223, 262
Rauschäquivalente Zählrate 126
Rekombinantes
humanes TSH.................... 21
Rekonstruktionsalgorithmus .. 35
RIS ...................................... 139
ROC-Analyse ........................ 49
SAP R/3 .............................. 139
Sauerstoffverbrauch.............. 10
Schilddrüse ......................... 206
Schwächungskorrektur........ 171
Sestamibi-Szintigraphie ...... 115
Skelettszintigraphie ............... 35
SomatostatinrezeptorSzintigraphie.................... 160
SPECT .... 35, 74, 111, 171, 254
Spiral-CT............................... 88
Staging................................ 235
Standardisierter
Uptake-Wert .................... 243
Strahlenexposition................. 82
Strahlenschutz .............. 82, 223
Strahlentherapie.................... 49
Strahlung............................. 229
Struma nodosa...................... 21
Subtraktionstechnik............. 115
Synovalitis........................... 262
99m
Tc-MIBI........................... 111
Tc-MIBI SPECT ................ 49
TcTUs ................................. 122
Thallium-201-Szintigraphie . 201
Therapieplanung ......... 134, 269
Thrombose.......................... 262
Tomographische Daten....... 269
Tumortherapie..................... 185
99m
Ultraschall ........................... 193
Untersuchungshäufigkeiten..... 1
Ösophaguskarzinom............235
Verweildauer ............... 134, 269
2-Phasen-Technik................115
PACS...................................139
Patientenexposition .................1
Perfusion ...............................10
PET... 10, 15, 88, 105, 153, 171,
193, 197, 248
PET/CT........................126, 219
PET-Leistungsdaten ............126
Pfortaderthrombose .............185
Workflow Nuklearmedizin.... 139
Yttrium-90 ............... 57, 82, 223
zervikale Lymphknoten ....... 243
Zevalin .................................. 82
VIII
Autoren – Nuklearmedizin 2006; 45 (1-6)
Altehoefer, C. ...................... 105
Amthauer, H. ................. 63, 177
Antke, C............................... 115
Athanasoulis, T..................... N4
Baehre, M............................ 153
Baller, D................................. 10
Bartenstein, P...................... 235
Barth, I................................... 82
Bauer, R. ............................... 57
Bauhofer, A. ........................ 206
Bautz, W................................ 88
Becherer, A. ........................ 171
Béhé, M. .............................. 206
Beheshti, M. ........................ 163
Behr, T.M..................... 122, 206
Berce, F............................... 206
Bercier, Y............................. 126
Berthold, F........................... 145
Beyer, T....................... 219, 229
Biersack, H.-J. ..................... 185
Bischof Delaloye, A. .............. 74
Blumstein, N.M. ................... 134
Bockisch, A.......................... 229
Boecker, H........................... 197
Börner, W. ........................... 139
Bokos, J................................ N4
Bongartz, R. ........................ 145
Brink, I. ................................ 193
Brix, G. .................................... 1
Brochhausen, C................... 235
Brunner, E. ............................ 35
Bucerius, J........................... 105
Buchmann, I. ....................... 235
Buchwald, B. ....................... 122
Buck, A.K............................. 134
Büther, F............................. N53
Bunjes, D............................. 134
Burchert, W. .......................... 10
Calcagni, M.L. ....................... 74
Chou, M.C. .......................... 201
Corstens, F.H.M. ......... 122, 206
Cupisti, K............................. 115
Czech, N.............................. 262
Czepczyński, R.................... 111
Daxböck, F. ......................... 160
Debus, J. ............................... 49
Dederichs, B.......................... 21
Denecke, T. ................... 63, 177
Dietlein, M. .................... 21, 145
Dobrozemsky, G.................. 163
Döbert, N............................. 243
Dorn, R................................ 101
Dudczak, R.......... 163, 171, 248
Dunkelmann, S.................... 213
Eberlein, U........................... 213
Eilles, Chr............................ 139
Eisenhut, M. .......................... 49
Engels, K............................. 243
Eschner, W.................. 145, 254
Felix, R. ................................. 63
Fiedler, E. ..............................88
Finke, J. ...............................105
Fischbach, R....................... N53
Fivaz-Arbane, M. ...................74
Freudenberg, L.S.................229
Fricke, E. ...............................10
Fröhlich, M. ............................63
Fuchs, E. .............................139
Fuechsel, F.G. .................... N42
Gaillard, R.C. .........................74
Gerl, J. .................................153
Geworski, L............................82
Glatting, G....................134, 269
Gmeiner, P.............................41
Goecke, J. ...................122, 206
Görges, R. ...........................229
Gotthardt, M.................122, 206
Graf, S. ................163, 171, 248
Gratz, S. ..............................262
Greess, H...............................88
Groth, P. ..............................213
Grothoff, M.............................63
Grünwald, F. ................185, 243
Gutberlet, M. ..................63, 177
Haberkorn, U. ........................49
Hacker, M. ...............................1
Hänninen, E.L. .....................177
Hänscheid, H. ........................82
Hahn, K....................................1
Halm, T. .................................82
Hansen, T. ...........................235
Hauser, A.I...........................197
Hausmann, H.........................63
Heidrich, G.............................35
Henriksen, G........................197
Henze, E..............................262
Henze, M. ..............................49
Herkel, C..............................105
Hero, B. .......................145, 254
Hetzer, R. ..............................63
Hildebrandt, B. .....................177
Hipp, P...................................49
Hocke, C................................41
Hodek-Wuerz, R. ................ N41
Hoegerle, S..........................193
Höpfner, S..............................15
Hofmann, A......................... N28
Hofmann, M. ..........................82
Hoier, S................................160
Holzinger, J............................10
Hopfenbach, A. ....................229
Hornegger, J. .........................88
Horstkotte, D..........................10
Hothorn, T..............................88
Huang, W.S. ........................201
Huber, K. .............................248
Hübner, H. .............................41
Jigalin, A..............................273
Joe, A.Y. ..............................105
John, P. .............................. N28
Junginger, T.........................235
Kammeier, A. ........................ 10
Kampen, W.U...................... 262
Kaźmierczak, M................... 111
Kessler, S.............................. 15
Khorsand, A. ....... 163, 171, 248
Klett, R. ......................... 57, 223
Kletter, K. ............ 163, 171, 248
Kneist, W............................. 235
Knoefel, W.-T. ..................... 115
Kobe, C. ................................ 21
Koehli, M. .............................. 74
Kopp, J................................ 101
Korovesis, K..........................N4
Koutsikos, J...........................N4
Kovács, A.F......................... 243
Kranert, W.T........................ 243
Krause, R. ........................... 160
Krause, T. ...........................N42
Krolak, C. .............................. 15
Künstner, H. ........................ 213
Kull, T.......................... 134, 269
Kurz, M................................ 139
Kuwert, T......................... 41, 88
Lamp, B. ............................... 10
Landmann, M. ..................... 269
Lange-Nolde, A. .................. 193
Langrehr, J.......................... 177
Lassmann, M......................... 82
Lee, J.K............................... 201
Lengsfeld, P. ....................... 223
Lerch, H. ............................. 273
Lindner, O. ............................ 10
Lipp, R.W. ........................... 160
Liu, R.S. .............................. 201
Löber, S. ............................... 41
Luger, A. .............................N64
Luig, H................................... 35
Männer, P. .......................... 139
Marienhagen, J. .................. 139
Martínez, M.-J. .................... 126
Matis, E. .............................. 262
Maurer, G. ................... 171, 248
Mehl, S.................................. 63
Meller, B.............................. 153
Meller, J. ............................... 35
Menzel, C. ................... 185, 243
Mier, W.................................. 49
Miersch, A. .......................... 177
Monbaron, D. ........................ 74
Moser, E...................... 105, 193
Mottaghy, F.M. .................... 269
Müller, H.-W. ....................... 115
Müller, S.P. ......................... 229
Mueller-Brand, J..................N41
Munz, D.L.............................. 82
Nabavi, E. ........................... 213
Nekolla, S.................... 171, 248
Neumaier, B. ....................... 134
Nicolaou, A.......................... 177
Nikfardjam, M. ..................... 248
Nömayr, A. ............................ 88
Noßke, D................................. 1
IX
Autoren – Nuklearmedizin 2006; 45 (1-6)
Oberholzer, K. ..................... 235
Özdemir-Sahin, N.................. 49
Oezer, S. ............................. 163
Ofluoglu, S........................... 248
Otto, I. ................................. 101
Oyen, W.J.G........................ 206
Palmedo, H.......................... 185
Pansegrau, J. ...................... 122
Pauleit, D............................. 185
Peloschek, P. ..................... N64
Pfahlberg, A........................... 88
Pfestroff, A................... 122, 206
Pirich, C....................... 163, 248
Piswanger-Soelkner, C........ 160
Platsch, G.............................. 88
Platzer, S............................. 197
Plotkin, M....................... 63, 177
Porenta, G. .......................... 171
Prante, O............................... 41
Prior, J.O. .............................. 74
Puille, M................................. 57
Rabe, C. .............................. 185
Range, F............................. N53
Raupach, R. ........................ 219
Reicherzer, H.G................... 139
Reichmann, K...................... 185
Reincke, M. ......................... 193
Reiners, Chr. ................... 97, 82
Reinhardt, M.J. .................... 105
Reisinger, E.C. .................... 160
Reske, S.N. ................. 134, 269
Richter, E............................. 153
Ricke, J. .............................. 177
Riess, H............................... 177
Rimpler, A.............................. 82
Risse, J.H............................ 185
Römer, W. ............................. 88
Rogacka, D.......................... 111
Rubner, C............................ 206
Rühl, R. ............................... 177
Ruf, J............................. 63, 177
Ruiz, J. .................................. 74
Sahlmann, C.O...................... 35
Sandrock, D........................... 82
Schaffarich, M.P. ................ N28
Schäfers, K.P. .............219, N53
Schäfers, M. ....................... N53
Schicha, H............. 21, 145, 254
Schlieck, A........................... 206
Schmid, E............................ 223
Schmidt, D........................... 115
Schmidt, M. ........... 21, 145, 254
Schnedl, W.J. ...................... 160
Schnell-Inderst, P. ................... 1
Schober, O. ........................ N53
Schönberger, J. ................... 139
Schommartz, B.................... 115
Schreckenberger, M. ........... 235
Schümichen, C. ................... 213
Schünemann, M. ................... 35
Schuler, G. ............................ 88
Schuler-Thurner, B. ...............88
Schwaiger, M. ..............126, 197
Sciuk, J. ...............................101
Siefker, U...............................35
Simon, T. .....................145, 254
Sinzinger, H. ....................... N28
Slawik, M. ............................193
Smolarek, I...........................111
Sochor, H.............................171
Sommer, K...........................153
Soti, Z. .................................262
Sowiński, J...........................111
Spilker, M.E. ........................197
Spors, B.................................63
Sprenger, T..........................197
Stamm-Meyer, A......................1
Staudenherz, A. .................. N28
Stauffer, J.C...........................74
Stegger, L. .......................... N53
Steiner, D...............................57
Stephan, G...........................223
Stix, G. .................................171
Stroszczynski, C. .................177
Strunk, H..............................185
Stübinger, M. .......................122
Sudbrock, F. ................145, 254
Surowiec, A..........................153
Tege, B. ...............................139
Theissen, P............................21
Tiling, R. ................................15
Toelle, T.R. ..........................197
Trautinger, F. ...................... N64
Vogt, H.................................101
Vogt, J. ..................................10
Von Hof, K. ..........................153
Voth, M. ...............................223
Walter, M.A. ........................ N41
Weidner, S.......................... N42
Wengenmair, H....................101
Werner, C. .............................35
Wester, H.-J.........................197
Wichter, T. .......................... N53
Wollenberg, B. .....................153
Wrba, F............................... N64
Wu, S.Y. ..............................201
Wunderlich, A. .....................269
Wysocki, H...........................111
Zajic, T.................................193
Zander, A...............................82
Zeittinig, G. ......................... N64
Zerva, C................................ N4
Ziegler, S.I. ..........................126
Zöphel, K. ..............................82
X

Index 45. Jahrgang, 2006 Inhalte Keywords

Transkript

Benzer belgeler

Inhaltsverzeichnis